Effectiveness of celadrin capsule in treatment of osteoarthritis

A comparison between the effectiveness of celadrin capsule (Rheumatidin) and meloxicam (nsaid) on reducing pain and improving clinical statement and physical function of patients with Knee Osteoarthritis.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180629040282N1

Enrollment

Registered

2019-04-18

Start date

2018-09-06

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Oral Rhomatidin ,350mg ceradrin capsule from weber natural company, 2 times a day for 30 days. Intervention 2: Control group: meloxicam, 15mg tablet from Irandaroo

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient should fill and sign the consent Patient should exprience pain and other sign and symptoms of knee osteoartritis during previous month Patient's age should be between 35-70

Exclusion criteria

Exclusion criteria: DM rheumatological disease involving the knee joints BMI more than 42 history of knee trauma or fracture during the 3 last months cancer bleeding disorders using anticoagulant drug pregnancy

Design outcomes

Primary

Measure	Time frame
Knee pain. Timepoint: Data about knee pain were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Visual Analogue Scale questionier.;Knee pain. Timepoint: Data about knee pain were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: oxford knee scale questionier.;Knee stiffness. Timepoint: Data about knee stiffness were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Western ontairo and mcmaster universities arthritis index questionier.;Knee function. Timepoint: Data about knee function were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Western ontairo and mcmaster universities arthritis index questionier.	—

Measure

Time frame

Knee pain. Timepoint: Data about knee pain were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Visual Analogue Scale questionier.;Knee pain. Timepoint: Data about knee pain were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: oxford knee scale questionier.;Knee stiffness. Timepoint: Data about knee stiffness were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Western ontairo and mcmaster universities arthritis index questionier.;Knee function. Timepoint: Data about knee function were obtained from the patient before the first dose of celadrin at the baseline and two and four and eight weeks after treatment (celadrin). Method of measurement: Western ontairo and mcmaster universities arthritis index questionier.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact??Sepide Mohebi

Shiraz University of Medical Sciences

Mohebi_sepideh@sums.ac.ir+98 71 3230 5884

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026